| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6784372aa482f6c62b3c468693641159
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_537aedd607603b452a2b475a3d3afe1f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-755
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 |
| filingDate |
2018-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac8ae5611d561bc631da7b2f2d46c7b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa877f4d3f57ebab0c2ca141d9f01536
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b35a59ef238d5eee9e227525458b3fcb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2316972d9b7204ca2a51ccca0e34b400
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d587e0ca8066649698d752f2b76f06d4 |
| publicationDate |
2019-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2019077690-A |
| titleOfInvention |
Methods of reducing immunogenicity to factor VIII in individuals receiving factor VIII therapy |
| abstract |
The present invention provides a method for reducing the immunogenicity to factor VIII in an individual receiving factor VIII therapy. The disclosure relates to a chimeric hybrid hybrid comprising FVIII and Fc for a subject at risk of developing an inhibitory FVIII immune response (including anti-FVIII antibody and / or cell-mediated immunity). Provided are methods of administering a factor VIII (FVIII) polypeptide. This administration is sufficient to promote coagulation and induce immune tolerance to FVIII. The chimeric polypeptide may comprise full-length FVIII, or a FVIII polypeptide comprising a deletion (eg, a complete or partial deletion of the B domain). [Selected figure] Figure 1 |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021020950-A |
| priorityDate |
2012-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |